Literature DB >> 28502479

Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.

Belinda B Guo1, Richard J Allcock2, Bob Mirzai2, Jacques A Malherbe1, Fizzah A Choudry3, Mattia Frontini4, Hun Chuah5, James Liang6, Simon E Kavanagh6, Rebecca Howman2, Willem H Ouwehand7, Kathryn A Fuller2, Wendy N Erber8.   

Abstract

Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoietic stem cell disorders associated with hyperproliferation of myeloid cells. They are driven by mutations in the hemopoietic stem cell, most notably JAK2V617F, CALR, and MPL. Clinically, they have the propensity to progress to myelofibrosis and transform to acute myeloid leukemia. Megakaryocytic hyperplasia with abnormal features are characteristic, and it is thought that these cells stimulate and drive fibrotic progression. The biological defects underpinning this remain to be explained. In this study we examined the megakaryocyte genome in 12 patients with MPNs to determine whether there are somatic variants and whether there is any association with marrow fibrosis. We performed targeted next-generation sequencing for 120 genes associated with myeloid neoplasms on megakaryocytes isolated from aspirated bone marrow. Ten of the 12 patients had genomic defects in megakaryocytes that were not present in nonmegakaryocytic hemopoietic marrow cells from the same patient. The greatest allelic burden was in patients with increased reticulin deposition. The megakaryocyte-unique mutations were predominantly in genes that regulate chromatin remodeling, chromosome alignment, and stability. These findings show that genomic abnormalities are present in megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow fibrosis.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28502479      PMCID: PMC5500825          DOI: 10.1016/j.ajpath.2017.03.009

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice).

Authors:  Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 2.  Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation.

Authors:  Olivier Garraud; Fabrice Cognasse
Journal:  Inflamm Allergy Drug Targets       Date:  2010-12

Review 3.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

4.  EZH2 mutational status predicts poor survival in myelofibrosis.

Authors:  Paola Guglielmelli; Flavia Biamonte; Joannah Score; Claire Hidalgo-Curtis; Francisco Cervantes; Margherita Maffioli; Tiziana Fanelli; Thomas Ernst; Nils Winkelman; Amy V Jones; Katerina Zoi; Andreas Reiter; Andrew Duncombe; Laura Villani; Alberto Bosi; Giovanni Barosi; Nicholas C P Cross; Alessandro M Vannucchi
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

5.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

Authors:  J L Villeval; K Cohen-Solal; M Tulliez; S Giraudier; J Guichard; S A Burstein; E M Cramer; W Vainchenker; F Wendling
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

Review 6.  Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

Authors:  S Koschmieder; T I Mughal; H C Hasselbalch; G Barosi; P Valent; J-J Kiladjian; G Jeryczynski; H Gisslinger; J S Jutzi; H L Pahl; R Hehlmann; A Maria Vannucchi; F Cervantes; R T Silver; T Barbui
Journal:  Leukemia       Date:  2016-02-08       Impact factor: 11.528

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 9.  MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target.

Authors:  Bozena Kaminska; Agata Gozdz; Malgorzata Zawadzka; Aleksandra Ellert-Miklaszewska; Maciej Lipko
Journal:  Anat Rec (Hoboken)       Date:  2009-12       Impact factor: 2.064

10.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

View more
  6 in total

Review 1.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

Review 2.  Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Moshe Talpaz; Jean-Jacques Kiladjian
Journal:  Leukemia       Date:  2020-07-09       Impact factor: 11.528

3.  Sequencing Directly from Clinical Specimens Reveals Genetic Variations in HCMV-Encoded Chemokine Receptor US28 That May Influence Antibody Levels and Interactions with Human Chemokines.

Authors:  Shelley Waters; Mark Agostino; Silvia Lee; Ibnu Ariyanto; Nina Kresoje; Shay Leary; Kylie Munyard; Silvana Gaudieri; Jessica Gaff; Ashley Irish; Anthony D Keil; Patricia Price; Richard J N Allcock
Journal:  Microbiol Spectr       Date:  2021-10-27

Review 4.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 5.  Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.

Authors:  Dragana Marković; Irina Maslovarić; Dragoslava Djikić; Vladan P Čokić
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

6.  Mutation profile of acute myeloid leukaemia in a Chinese cohort by targeted next-generation sequencing.

Authors:  Benny Man Wai Lit; Belinda B Guo; Jacques A J Malherbe; Yok Lam Kwong; Wendy N Erber
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.